Research Article

Nosocomial Isolates and Their Drug Resistant Pattern in ICU Patients at National Institute of Neurological and Allied Sciences, Nepal

Pashupati Bhandari,1 Ganesh Thapa,2 Bharat Mani Pokhrel,3 Dwij Raj Bhatta,1 and Upendra Devkota2

1Central Department of Microbiology, Tribhuvan University, Kathmandu 44601, Nepal
2National Institute of Neurological and Allied Sciences (NINAS), Kathmandu 3711, Nepal
3Department of Microbiology, Institute of Medicine (IOM), Tribhuvan University, Kathmandu 1524, Nepal

Correspondence should be addressed to Pashupati Bhandari; pashupati.microxpress@gmail.com

Received 3 August 2015; Revised 27 September 2015; Accepted 7 October 2015

Academic Editor: Barbara H. Iglewski

Copyright © 2015 Pashupati Bhandari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Multidrug resistant organisms are increasing day by day and the cause is poorly known. This study was carried out from June 2011 to May 2012 at National Institute of Neurological and Allied Sciences Kathmandu, Nepal, with a view to determining drug resistant pathogens along with detection of extended spectrum β-lactamase (ESBL), AmpC β-lactamase (ABL), and metallo-β-lactamase (MBL) producing bacteria causing infection to ICU patients. A standard methodology was used to achieve these objectives as per recommendation of American Society for Microbiology. ESBL was detected by combined disc assay using cefotaxime and cefotaxime clavulanic acid, ABL by inhibitor based method using cefoxitin and phenylboronic acid, and MBL by imipenem-EDTA combined disk method. Two hundred and ninety-four different clinical samples such as tracheal aspirates, urine, pus, swabs, catheter tips, and blood were processed during the study. Most common bacteria were Acinetobacter spp. Of the total 58 Acinetobacter spp., 46 (79%) were MDR, and 27% were positive for ABL and 12% were for MBL. Of the 32 cases of Staphylococcus aureus, 18 (56%) were MDR. Findings of this study warrant routine β-lactamase testing in clinical isolates.

1. Introduction

Intensive care unit patients are at greater risk to acquire nosocomial infection because of invasive procedures, prolonged hospital stay, high antibiotic use, cross transmission among patients and staffs, and inadequate infection control procedures which predisposes ICU as a suitable place for emergence and spread of nosocomial infections [1–3]. Most common and frequently reported nosocomial infections in ICU are urinary tract infection, ventilator associated pneumonia (VAP), surgical site infection, catheter site infection, bacteremia, and other infections like skins and soft tissue infections and common bacteria involved in such infections are Pseudomonas aeruginosa, Acinetobacter spp., S. aureus, E. coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus spp., and others [4]. Sources of these organisms may be patients own flora, visitors, ICU environment like water, air, foods, and equipments, health care workers, other patients, or inanimate objects that are in close vicinity of patients [5].

Antimicrobial resistance in nosocomial infections is increasing with both morbidity and mortality especially when the infection is caused by the multidrug resistance organism [6]. More than 2 million patients are affected each year which accounts approximately for up to 10% of hospitalized patients leading to approximately 90,000 deaths per year because of nosocomial infection only [7]. Several different mechanisms for bacterial drug resistance have been described, for example, production of different drug inactivating enzymes like β-lactamases, multiple efflux pump, and reduced uptake [8].
This emergence and spread of antimicrobial resistance due to the production of different β-lactamases thus demand continual monitoring of resistance and rapid identification of such resistant organisms and determine their prevalence. Hence, this study was conducted with an aim to determine prevalence and resistance pattern of clinically relevant β-lactamase producers and to find antibacterial drug that could be used in therapeutics.

2. Methodology

This cross-sectional study was conducted from June 2011 to May 2012 at National Institute of Neurological and Allied Sciences, Kathmandu, Nepal.

2.1. Specimen Size and Types. 294 different clinical samples, which are 152 tracheal aspirates, 43 urine samples, 31 pus/ wound swabs, 24 each of CSF and CVP tips, 9 blood samples, 5 catheter tips, 2 nasal swabs, and one sample each of trans-sphenoidal mucosa, tissue from meningococcal cell, sputum and bone sent from ICU for routine culture, and antibiotic susceptibility tests, were processed during study period.

2.2. Culture. Urine specimens were cultured by semiquantitative culture technique. For urine and tracheal aspirates, a loop full of well-mixed and uncentrifuged samples was inoculated onto Blood agar (BA) and MacConkey agar (MA) and aerobically incubated at 37°C for 24 hours. CSF, pus and wound swabs were inoculated onto Blood agar (BA), MacConkey agar (MA), and Chocolate agar (CA). The BA and CA plates were incubated at 5–10% CO2 enriched atmosphere whereas MA was incubated aerobically at 37°C for 24 hours. Similarly tips were rolled over on the surface of the Blood agar (BA) and MacConkey agar (MA) and incubated at 37°C for 24 hours. Blood samples were first enriched on the Brain Heart Infusion broth for 48 hours and then subcultured on MA and BA every 24 hours for 3 days [9].

2.3. Identification of Isolates. At first colony characteristics of isolated organisms were observed on agar plates and Gram staining was performed. Gram positive isolates were further identified by using catalase, oxidase, coagulase, and optochin sensitivity tests while for identification of Gram negative isolates different biochemical tests like catalase, oxidase, motility, H2S and indole production, citrate utilization, MR-VP, urea hydrolysis, and triple sugar iron utilization were done and then identified based on their results.

2.4. Antibiotic Susceptibility Test. Antimicrobial susceptibility of bacterial isolates was determined by Kirby-Bauer disk diffusion method as recommended by CLSI. Using sterile loop four to five different colonies of test organism were mixed with 2 mL of sterile saline and vortexed to create a smooth suspension. Turbidity of this solution is adjusted to a 0.5 McFarland standard which has corresponding bacterial concentration of approximately 150 million/mL. A sterile swab is then dipped into the suspension, firmly pressed to remove excess fluid, and plated on Muller Hinton agar. Discs were then applied on MHA plates and incubated at 37°C for 24 hours. Zone of inhibition was measured and interpreted using the standard chart and organisms reported as susceptible, intermediate, or resistant accordingly [10]. Antibiotic discs were obtained from HiMedia, Mumbai, India, and MAST Diagnostics, Merseyside, England.

2.5. Criterion for Multidrug Resistance. In this study, the defining criterion for an isolate to be multidrug resistant (MDR) was set as resistance to three or more drugs belonging to different structural classes [11].

2.6. Test for ESBL, ABL, and MBL Production. To test for ESBL production, test organism inoculum that matches McFarland tube number 0.5 turbidity was made and carpet cultured on Mueller-Hinton agar plate using sterile swab and cefotaxime (30 μg) (Mast Diagnostics, UK) was applied as screening agents incubated at 37°C for 18–24 hours. Isolates showing zone of inhibition <27 mm to cefotaxime were considered as possible ESBL producers. This zone of inhibition for the cefotaxime was compared with cefotaxime (30 μg) plus clavulanic acid (10 μg) combination discs; an increase in zone diameter of ≥5 mm in the presence of cefotaxime plus clavulanic acid from cefotaxime alone is confirmed as ESBL producers [12].

Test organisms were screened for ABL production by using cefoxitin (30 μg) disc; isolates showing zone diameters less than 18 mm were considered as screen-positive for ABL production. Screen-positive isolates were confirmed by inhibitor based method. Phenylboronic acid was prepared by dissolving 120 mg of it in 3 mL of DMSO and then 3 mL of sterile distilled water was added. Combined disc was prepared by dispensing 20 μL phenylboronic acid solution to 30 μg cefoxitin disc. Test was then performed by placing a disc containing 30 μg cefoxitin along with a previously made combined disc containing cefoxitin and phenyl boronic acid in MHA plates by standard disc diffusion method. Plates were incubated at 37°C for 18–24 hours and zone diameter was measured. Isolates showing diameter of ≥5 mm, of zone around combined disc as compared to that of zone diameter cefoxitin disc alone, were considered as AmpC producer [13].

For MBL detection, imipenem (10 μg) disc was used as a screening agent; test organisms showing intermediate or resistant zone diameter in disk diffusion method as recommended by CLSI guidelines were considered as screen-positive for MBL production. To confirm MBL detection, a 0.5 McFarland bacterial suspension was inoculated on MHA plates and two imipenem (10 μg) discs were applied on the plate and in one disc 10 μL of 100 mM EDTA was added directly. Plates were incubated at 37°C for 18–24 hours. Isolates showing diameter of ≥5 mm, of zone around combined imipenem-EDTA disc as compared to that of imipenem discs alone, were considered as MBL producer [14].

3. Results

Out of 294 total samples processed during the study, 179 (60.8%) showed significant growth with 8 polymicrobial growths. Tracheal aspirates 152 (51.7%) was the most common sample followed by urine and pus with 43 (14.6%) and 31
Table 1: Growth pattern and distribution of MDR isolates in different samples.

| Specimen            | Number of samples | Growth number (%) | Number (%) of MDR strains |
|---------------------|-------------------|-------------------|---------------------------|
| Tracheal aspirates  | 152               | 113 (74.3)        | 94 (83.1)                 |
| Urine               | 43                | 25 (58.2)         | 19 (44.1)                 |
| Pus/wound swab      | 31                | 18 (58.1)         | 12 (66.6)                 |
| CVP tip             | 24                | 10 (41.6)         | 10 (100)                  |
| CSF                 | 24                | 4 (17.3)          | 3 (75)                    |
| Blood               | 9                 | 1 (11.1)          | 0                         |
| ICP catheter        | 3                 | 1 (25)            | 1 (33.3)                  |
| EVD drain tip       | 2                 | 2 (100)           | 2 (100)                   |
| Nasal swab          | 2                 | 2 (100)           | 0                         |
| Others              | 4                 | 3 (75)            | 1 (33.3)                  |
| Total               | 294               | 179 (60.88)       | 142 (79.3)                |

Others include tissue from meningococcal cell, transsphenoidal mucosa, bone, and sputum.

(10.5%) samples, respectively. Of the 152 tracheal aspirates samples, 113 (74.3%) showed significant growth among which 94 (83.1%) were MDR strains. Similarly, 25 (58.2%) and 18 (58.1%) urine and pus swab showed significant growth, respectively, among which 19 (44.1%) and 12 (66.6%) were MDR. The growth pattern and distribution of multidrug resistant isolates in different samples are presented in Table 1.

Out of 187 total isolates, 149 (79.67%) were Gram negatives and 121 (68.2%) of them were MDR. Acinetobacter spp. were the most frequently isolated among Gram negatives with 58 (38.9%) isolates and among them 46 (79.31%) were MDR. This was followed by K. oxytoca with 23 (15.4%) isolates, 20 (86.95%) of them being MDR. Similarly, out of 38 total Gram positive isolates, 21 (55.2%) were MDR and Staphylococcus aureus was the most common Gram positive cocci with 32 (84.2%) isolates; among them, 8 (56.25%) were MDR. The detailed results are given in Table 2.

High resistant rates of Acinetobacter spp. were found against antibiotics like gentamycin (70.68%), cefotaxime (82.75%), ciprofloxacin (82.75%), cefepime (86.2%), and cotrimoxazole (93.83%). Similarly, high resistance to cefotaxime and gentamycin (82.6%) each, cotrimoxazole (83.3%), ciprofloxacin and cefepime (93.1%) each, and ampicillin (100%) was found against K. oxytoca. Polymyxin B was found to be drug with highest sensitivity of 100% against all isolates of Gram negative rods. Detailed results are shown in Table 3.

Staphylococcus aureus was the major Gram positive isolate which showed higher rate of resistance to ampicillin (78.1%) while it showed sensitivity of 100% against vancomycin, followed by gentamycin (78.12%). Results are shown in Table 4.

ESBL was confirmed in 40 (32.25%) isolates; among them 10 (25%) were E. coli followed by 8 (20%) isolates of K. oxytoca. ABL was detected in 51 (31.28%) isolates and Acinetobacter spp. 16 (31.37%) were major ABL producers. MBL production was found in 11 isolates; among them, 7 (63.8%) were Acinetobacter spp. followed by 2 (18.1%) isolates each of K. oxytoca and K. pneumonia. Detailed results are presented in Table 5.

4. Discussion

In this study high growth rate was found from different clinical samples, and similar results have been reported in the previous study carried out at the same hospital [15, 16]. Most predominant pathogens in this study were Acinetobacter spp. which was in accordance with a previous study [17]. However, in other studies [18, 19] it has been shown that Klebsiella spp. are major nosocomial pathogens of ICU. This difference may be attributed to difference in geographical location, nutritional status, health care settings, and immune status of patient. Acinetobacter was also reported as the most pathogen recovered from intensive care unit patients in an international study of prevalence of “Infections in Intensive Care study” [20].

In this study, 86.9% of K. oxytoca, 84.21% of Pseudomonas spp., 81.81% of K. pneumoniae, and 79.31% of Acinetobacter spp. were multidrug resistant and similar result was also reported in an earlier study [16]. Production of different β-lactamases, multiple efflux pumps, decreased uptake, and other drug modifying enzymes contribute to a greater role for drug resistance in Klebsiella spp. and similar resistance mechanism also occurs in Acinetobacter spp. and Pseudomonas spp. [21, 22].

A higher prevalence (32.25%) of ESBL production was found in E. coli followed by K. oxytoca and K. pneumoniae which is in agreement with a previous study that reports a prevalence rate of 28.6%. E. coli and K. pneumoniae isolates are known to produce SHV, TEM, CTX-M, and PER types of ESBLs and show variable resistance to β-lactam antibiotics resulting in therapeutic failure [23]. Several risk factors exist for colonization and infection with ESBL producer like seriously ill patients with prolonged hospital stay, use of invasive devices, heavy and prior antibiotic use, poor nutritional status, recent surgery, gastrostomy, total parenteral nutrition, and hemodialysis [24].

High prevalence of AmpC β-lactamase was detected in Acinetobacter spp. (29.4%) followed by Staphylococcus aureus (21.5%) and K. oxytoca (15.6%) which follows pattern in accordance with the previous result [25] with a prevalence rate of 20% in Klebsiella spp. High level of AmpC production is typically associated with the resistance to all β-lactam antibiotics except carbapenems and limits the therapeutic use. Sensitivity and specificity of the method used in this study are 90% and 98.2%, respectively [13].

In 11 isolates MBL was detected out of 17 screen-positive isolates with prevalence rate of 64.7%; among them...
### Table 2: Frequency of bacterial isolates and their multidrug resistant profile.

| SN | Bacterial isolates         | Total isolate number | Multidrug resistance isolates number (%) |
|----|----------------------------|----------------------|-----------------------------------------|
| 1  | Acinetobacter spp.         | 58                   | 46 (79.31)                              |
| 2  | K. oxytoca                 | 23                   | 20 (86.95)                              |
| 3  | K. pneumoniae              | 22                   | 18 (81.81)                              |
| 4  | E. coli                    | 19                   | 14 (73.62)                              |
| 5  | Pseudomonas spp.           | 19                   | 16 (84.21)                              |
| 6  | Citrobacter spp.           | 3                    | 2 (66.66)                               |
| 7  | P. vulgaris                | 3                    | 3 (100)                                 |
| 8  | P. mirabilis               | 2                    | 2 (100)                                 |
| 9  | Staphylococcus aureus      | 32                   | 18 (56.25)                              |
| 10 | β-hemolytic streptococci   | 3                    | 3 (100)                                 |
| 11 | Viridans streptococci      | 2                    | 0                                       |
| 12 | Coagulase negative staphylococci | 1 | 0                               |
|    | Total                      | 187                  | 142 (75.93)                             |

Multidrug resistance criteria: resistance to three or more drugs of different structural classes.

### Table 3: Antibiotics profile of major Gram negative pathogens.

| Antibiotics       | Acinetobacter spp. (n = 58) | K. oxytoca (n = 23) | K. pneumoniae (n = 22) | Pseudomonas spp. (n = 19) | E. coli (n = 19) |
|-------------------|------------------------------|---------------------|------------------------|---------------------------|-----------------|
| Ampicillin        | NT                           | 100                 | 100                    | NT                        | 78.11           |
| Amikacin          | 67.24                        | 73.91               | 59.09                  | 31.57                     | 19.04           |
| Cotrimoxazole     | 93.83                        | 83.31               | 81.8                   | 84.21                     | 68.85           |
| Cefotaxime        | 82.75                        | 82.6                | 81.0                   | 73.68                     | 78.94           |
| Cefépine          | 86.20                        | 91.3                | 81.81                  | 84.4                      | 57.8            |
| Carbenicillin     | NT                           | NT                  | NT                     | 42.1                      | NT              |
| Ciprofloxacin     | 82.75                        | 91.3                | 68.18                  | 73.68                     | 73.68           |
| Gentamycin        | 70.68                        | 82.6                | 59.09                  | 42.1                      | 47.36           |
| Imipenem          | 17.24                        | 0                   | 18.18                  | 0                         | 0               |
| Ofloxacin         | 68.96                        | 60.80               | 63.63                  | 47.36                     | 63.15           |
| Piperacillin/tazobactam | 50.02               | 40.90               | 63.15                  | 5.26                      | 15.78           |
| Polymyxin B       | 0                            | 0                   | 0                      | 0                         | 0               |

NT: not tested.

### Table 4: Antibiotic susceptibility profile of S. aureus (n = 32).

| Antibiotic used | Sensitive Number | Sensitive % | Resistant Number | Resistant % |
|-----------------|------------------|-------------|------------------|-------------|
| Ampicillin      | 7                | 21.9        | 25               | 78.1        |
| Cotrimoxazole   | 18               | 56.25       | 14               | 43.7        |
| Cefotaxime      | 19               | 59.38       | 13               | 40.62       |
| Cefoxitin       | 18               | 56.25       | 14               | 43.75       |
| Ciprofloxacin   | 23               | 71.87       | 9                | 28.12       |
| Cloxacillin     | 20               | 62.5        | 12               | 37.5        |
| Gentamycin      | 25               | 78.12       | 7                | 21.87       |
| Methicillin     | 22               | 68.75       | 10               | 31.25       |
| Ofloxacin       | 24               | 75          | 8                | 25          |
| Vancomycin      | 100              | 100         | 0                | 0           |

7 (63.63%) were Acinetobacter spp. and the rest Klebsiella spp. Different transferable MBL is found in these organisms and major ones are IMP, VIM, and SIM type [26]. Contrary to current finding a Korean survey showed only 6% MBL positive isolates [27]. The increasing trend of carbapenem resistance in Acinetobacter spp. worldwide poses a significant concern since it limits the range of therapeutic alternative. Carbapenem resistance in Acinetobacter is due to naturally occurring β-lactamases, acquired β-lactamases like metallo-β-lactamases, carbapenem hydrolyzing oxacillinases (CHDLs), loss of outer membrane porin protein, and sometimes modification in penicillin-binding protein [28].

### 5. Conclusion

Acinetobacter spp. and S. aureus were major pathogens prevalent in ICU of National Institute of Neurological and
Table 5: ESBL versus ABL versus MBL producing bacteria.

| Bacteria            | ESBL production number (%) | ABL production number (%) | MBL production number (%) |
|---------------------|----------------------------|----------------------------|---------------------------|
| E. coli             | 10 (25%)                   | 4 (7.8%)                   | 0                         |
| K. oxytoca          | 8 (20%)                    | 8 (15.6%)                  | 2 (18.1%)                 |
| K. pneumoniae       | 6 (15%)                    | 6 (11.7%)                  | 2 (18.1%)                 |
| Acinetobacter spp.  | 5 (12.5%)                  | 16 (31.37%)                | 7 (63.8%)                 |
| Pseudomonas spp.    | 5 (12.5%)                  | 4 (7.8%)                   | 0                         |
| Citrobacter spp.    | 1 (2.5%)                   | 2 (3.9%)                   | 0                         |
| P. mirabilis        | 1 (2.5%)                   | 0                          | 0                         |
| P. vulgaris         | 1 (2.5%)                   | 0                          | 0                         |
| S. aureus           | 3 (7.5%)                   | 11 (21.5%)                 | 0                         |
| Total               | 40 (32.25%)                | 51 (31.28%)                | 11 (64.7%)                |

Allied Sciences during the study. Inclusion of ESBL, ABL, and MBL in clinical isolates is warranted.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to thank University Grant Commission, Nepal, for providing financial support for this work and NINAS for allowing conducting this study. They are grateful to the patients of NINAS without whom this work would not have been possible.

References

[1] D. J. Weber, W. A. Rutala, E. E. Sickbert-Bennett, G. P. Samsa, V. Brown, and M. S. Niederman, "Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia," *Infection Control & Hospital Epidemiology*, vol. 28, no. 7, pp. 825–831, 2007.

[2] P. E. Fournier and H. Richet, "The epidemiology and control of *Acinetobacter baumannii* in health care facilities," *Clinical Infectious Diseases*, vol. 42, no. 5, pp. 692–699, 2006.

[3] E. G. Playford, J. C. Craig, and J. R. Iredell, "Carbapenem-resistant *Acinetobacter baumannii* in intensive care unit patients: risk factors for acquisition, infection and their consequences," *Journal of Hospital Infection*, vol. 65, no. 3, pp. 204–211, 2007.

[4] Y. A. Hanifah and M. Yosuf, "Nosocomial infection in intensive care units," *The Malaysian Journal of Pathology*, vol. 13, no. 1, pp. 33–35, 1991.

[5] G. Ducel, *Prevention of Hospital-Acquired Infections: A Practical Guide*, WHO Press, Geneva, Switzerland, 2nd edition, 2002.

[6] K. Mohanasoundaram, "Retrospective analysis of incidence of nosocomial infections in ICU," *Journal of Clinical and Diagnostic Research*, vol. 4, pp. 3378–3382, 2010.

[7] R. R. Roberts, R. Scott, R. Cordell et al., "The use of economic modeling to determine the hospital costs associated with nosocomial infection," *Critical Care Medicine*, vol. 27, no. 5, pp. 887–892, 2003.

[8] D. K. Byarugaba, "Antimicrobial resistance in developing countries and responsible risk factors," *International Journal of Antimicrobial Agents*, vol. 24, no. 2, pp. 105–110, 2004.

[9] B. A. Forbes, D. F. Sahm, and A. S. Weisfled, *Bailey and Scott’s Diagnostic Microbiology*, Mosby, 12th edition, 2007.

[10] Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement," CLSI Document M100-S19, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2009.

[11] A.-P. Magiorakos, A. Srinivasan, R. B. Carey et al., "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance," *Clinical Microbiology and Infection*, vol. 18, no. 3, pp. 268–281, 2012.

[12] D. L. Paterson and R. A. Bonomo, "Extended-spectrum β-lactamases: a clinical update," *Clinical Microbiology Reviews*, vol. 18, no. 4, pp. 657–686, 2005.

[13] P. E. Coudron, "Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in *Klebsiella* spp., *Escherichia coli*, and *Proteus mirabilis*," *Journal of Clinical Microbiology*, vol. 43, no. 8, pp. 4163–4167, 2005.

[14] R. C. Picão, S. S. Andrade, A. G. Nicoletti et al., "Metallo-β-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates," *Journal of Clinical Microbiology*, vol. 46, no. 6, pp. 2028–2037, 2008.

[15] P. Koirala, D. R. Bhatta, P. Ghimire et al., "Bacteriological profile of tracheal aspirates of the patients attending a neuro-hospital of Nepal," *International Journal of Advanced Life Sciences*, vol. 2, no. 4, pp. 60–65, 2010.

[16] S. Khanal, D. R. Joshi, D. R. Bhatta, U. Devkota, and B. M. Pokhrel, "β-lactamase-producing multidrug-resistant bacterial pathogens from tracheal aspirates of intensive care unit patients at National Institute of Neurological and Allied Sciences, Nepal," *ISRN Microbiology*, vol. 2013, Article ID 847569, 5 pages, 2013.
[17] R. B. Patwardhan, P. K. Dhakephalkar, K. B. Niphadkar, and B. A. Chopade, "A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harbouring multiple plasmids," *Indian Journal of Medical Research*, vol. 128, no. 2, pp. 178–187, 2008.

[18] H. Mythri and K. Kashinath, "Nosocomial infections in patients admitted in intensive care unit of a Tertiary Health Center, India," *Annals of Medical and Health Sciences Research*, vol. 4, no. 5, pp. 738–741, 2014.

[19] M. Radji, S. Fauziah, and N. Aribinuko, "Antibiotic sensitivity pattern of bacterial pathogens in the intensive care unit of Fatmawati Hospital, Indonesia," *Asian Pacific Journal of Tropical Biomedicine*, vol. 1, no. 1, pp. 39–42, 2011.

[20] J.-L. Vincent, J. Rello, J. Marshall et al., "International study of the prevalence and outcomes of infection in intensive care units," *The Journal of the American Medical Association*, vol. 302, no. 21, pp. 2323–2329, 2009.

[21] F. C. Tenover, "Mechanisms of antimicrobial resistance in bacteria," *American Journal of Medicine*, vol. 119, no. 6, pp. S3–S10, 2006.

[22] D. M. Livermore, "β-lactamases in laboratory and clinical resistance," *Clinical Microbiology Reviews*, vol. 8, no. 4, pp. 557–584, 1995.

[23] S. Shrestha, R. Amatya, and R. Dutta, "Prevalence of extended spectrum β-lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of eastern Nepal," *Nepal Medical College Journal*, vol. 13, no. 3, pp. 186–189, 2011.

[24] A. Gori, F. Espinasse, A. Deplano, C. Nonhoff, M. H. Nicolas, and M. J. Struelens, "Comparison of pulsed-field gel electrophoresis and randomly amplified DNA polymorphism analysis for typing extended-spectrum-β-lactamase-producing Klebsiella pneumoniae," *Journal of Clinical Microbiology*, vol. 34, no. 10, pp. 2448–2453, 1996.

[25] T. Y. Tan, S. Y. Ng, L. Teo, Y. Koh, and C. H. Teok, "Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis," *Journal of Clinical Pathology*, vol. 61, no. 5, pp. 642–644, 2008.

[26] T. R. Walsh, M. A. Toleman, L. Poirel, and P. Nordmann, "Metallo-β-lactamases: the quiet before the storm?" *Clinical Microbiology Reviews*, vol. 18, no. 2, pp. 306–325, 2005.

[27] K. Lee, Y. S. Lim, D. Yong, J. H. Yum, and Y. Chong, "Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.," *Journal of Clinical Microbiology*, vol. 41, no. 10, pp. 4623–4629, 2003.

[28] L. Poirel and P. Nordmann, "Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology," *Clinical Microbiology and Infection*, vol. 12, no. 9, pp. 826–836, 2006.